Literature DB >> 12433888

The economic burden of coronary heart disease in the UK.

J L Y Liu1, N Maniadakis, A Gray, M Rayner.   

Abstract

OBJECTIVE: To estimate the economic burden of coronary heart disease in the UK using both direct and indirect costs. DESIGN AND
SETTING: A prevalence based approach was used to assess coronary heart disease related costs from the societal perspective. PATIENTS: All UK residents in 1999 with coronary heart disease (ICD 9 codes 410-414 and ICD10 codes I20-I25). MAIN OUTCOME MEASURES: Direct health care costs were estimated from spending on prevention, accident and emergency care, hospital care, rehabilitation, and drug treatment. Direct non-health service costs were estimated from data on informal care. "Friction period" adjusted productivity costs were estimated using the human capital approach from lost earnings attributable to coronary heart disease related mortality and morbidity. The friction period is the period of employees' absence from work before the employer replaces them with other workers. Failure to adjust for this factor would overstate production loss.
RESULTS: Coronary heart disease cost pound 1.73 billion to the UK health care system in 1999: pound 2.42 billion in informal care and pound 2.91 billion in friction period adjusted productivity loss; 24.1% of production losses were attributable to mortality and 75.9% to morbidity. The total annual cost of all coronary heart disease related burdens was pound 7.06 billion, the highest of all diseases in the UK for which comparable analyses have been done.
CONCLUSIONS: Coronary heart disease is a leading public health problem in the UK in terms of the economic burden from disease. Cost estimates would be substantially understated if informal care/productivity costs were excluded.

Entities:  

Mesh:

Year:  2002        PMID: 12433888      PMCID: PMC1767465          DOI: 10.1136/heart.88.6.597

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  The relation between funding by the National Institutes of Health and the burden of disease.

Authors:  C P Gross; G F Anderson; N R Powe
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

2.  The economic burden of back pain in the UK.

Authors:  N Maniadakis; A Gray
Journal:  Pain       Date:  2000-01       Impact factor: 6.961

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

4.  Economic burden of treated benign prostatic hyperplasia in the United Kingdom.

Authors:  M F Drummond; A J McGuire; N A Black; M Petticrew; C K McPherson
Journal:  Br J Urol       Date:  1993-03

5.  Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.

Authors:  J Posnett; S Jan
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

6.  Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

7.  Patterns and costs of hospital care for coronary heart disease related and not related to diabetes.

Authors:  C J Currie; C L Morgan; J R Peters
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

8.  Alzheimer's disease: the burden of the illness in England.

Authors:  A Gray; P Fenn
Journal:  Health Trends       Date:  1993

9.  What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.

Authors:  B Jönsson; P E Bebbington
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

10.  The cost of cardiac rehabilitation services in England and Wales.

Authors:  A M Gray; G S Bowman; D R Thompson
Journal:  J R Coll Physicians Lond       Date:  1997 Jan-Feb
View more
  48 in total

1.  The economic burden of atherothrombosis in Greece: results from the THESIS study.

Authors:  Nikos Maniadakis; Georgia Kourlaba; Dennis V Cokkinos; Aggeliki Angeli; John Kyriopoulos
Journal:  Eur J Health Econ       Date:  2012-07-10

2.  The hidden economic burden of air pollution-related morbidity: evidence from the Aphekom project.

Authors:  Olivier Chanel; Laura Perez; Nino Künzli; Sylvia Medina
Journal:  Eur J Health Econ       Date:  2015-12-09

3.  Obesity and the overworked GP.

Authors:  Sarah Jarvis
Journal:  Br J Gen Pract       Date:  2006-09       Impact factor: 5.386

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

6.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

7.  Relation between initial treatment strategy in stable coronary artery disease and 1-year costs in Ontario: a population-based cohort study.

Authors:  Jaskaran S Kang; Maria C Bennell; Feng Qiu; Merril L Knudtson; Peter C Austin; Dennis T Ko; Harindra C Wijeysundera
Journal:  CMAJ Open       Date:  2016-08-08

8.  Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Authors:  Kostas Athanasakis; Eleftheria Karampli; Dimitrios Tsounis; Aikaterini Bilitou; John Kyriopoulos
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

9.  Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000.

Authors:  Kathleen Bennett; Zubair Kabir; Belgin Unal; Emer Shelley; Julia Critchley; Ivan Perry; John Feely; Simon Capewell
Journal:  J Epidemiol Community Health       Date:  2006-04       Impact factor: 3.710

10.  Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives.

Authors:  Anthony Scott; Michela Tinelli; Christine Bond
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.